SLC5A2 and type 2 diabetes mellitus: This result contrasts with a review by Takebayashi and Inukai, which suggests that SGLT2 inhibitors may increase GLP-1 secretion in type 2 diabetes, and with the incidental findings of our previous pilot study [7, 9].